Haloperidol Use in First Trimester Pregnancy
Haloperidol can be used in the first trimester of pregnancy when the benefit clearly justifies the potential risk to the fetus, but there are reports of limb malformations following first-trimester exposure that warrant caution and careful risk-benefit assessment. 1
FDA Labeling Position
The FDA label explicitly states that haloperidol should be used during pregnancy "only if the potential benefit justifies the potential risk to the fetus." 1 Critically, the label notes:
- There are reports of limb malformations observed following maternal use of haloperidol along with other drugs during the first trimester
- Causal relationships were not established in these cases
- No well-controlled studies exist in pregnant women
- Animal studies showed no teratogenic effects in rats, rabbits, or dogs, though cleft palate occurred in mice at high doses
Evidence on Congenital Malformations
The concern about limb defects has some supporting evidence:
- A 2025 pharmacovigilance study found haloperidol had significantly higher reporting frequency for congenital malformations compared to quetiapine (ROR 3.83; 95% CI, 2.62-5.59) 2
- A 2005 prospective controlled study of 188 haloperidol-exposed pregnancies found no overall increase in major anomalies (3.4% vs 3.8% in controls), but identified 2 cases of limb defects in the exposed group versus none in controls 3
- Early case reports from 1975 documented severe limb malformations following first-trimester haloperidol exposure 4
Balanced Interpretation
The 2005 multicenter prospective study provides the most reassuring data, suggesting haloperidol "does not represent a major teratogenic risk" 3. However, the authors recommend level II ultrasound with emphasis on limbs for first-trimester exposures, acknowledging that "a possible association between butyrophenone exposure and limb defects cannot be ruled out."
Clinical Decision Framework
When considering haloperidol in first trimester:
Assess severity of maternal condition - Is the psychiatric condition severe enough that untreated illness poses greater risk than potential medication effects?
Consider alternatives - Second-generation antipsychotics like quetiapine may have more established safety profiles, though haloperidol remains a reasonable option for acute agitation 5
Use lowest effective dose - If haloperidol is chosen, minimize fetal exposure through dose optimization
Enhanced monitoring - Arrange detailed anatomical ultrasound at 18-20 weeks with specific attention to limb development 3
Document informed consent - Discuss the uncertain but possible association with limb malformations
Important Caveats
- The association with limb defects remains unproven and may reflect confounding by indication or polypharmacy
- For acute agitation in pregnancy requiring immediate management, haloperidol is considered a preferred high-potency typical antipsychotic due to neutral hemodynamic effects 5
- Third-trimester exposure carries different risks (neonatal extrapyramidal symptoms, withdrawal) that are separate from first-trimester teratogenic concerns 1